Donald Allen Williams - 20 Aug 2024 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Reporting relationship: Director
Issuer ticker: FBRX
Reported as of: 20 Aug 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Aug 2024, 16:07:40 UTC
Prior SEC filing: 15 Jul 2024
Next SEC filing: 22 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact

Key filing fact

Donald Allen Williams filed Form 4 for Forte Biosciences, Inc. (FBRX) on 22 Aug 2024.

Key facts

This page summarizes Donald Allen Williams's Form 4 filing for Forte Biosciences, Inc. (FBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Aug 2024, 16:07.

Change

Previous filing in this sequence was filed on 15 Jul 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FBRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 20 Aug 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.3440
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024.